Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,506.51
(
0.84%
)
US TECH 100
28,811.60
(
0.78%
)
Dow Jones
50,080.94
(
0.78%
)
Brent Oil
103.79
(
0.10%
)
Bitcoin
81,360.75
(
2.62%
)
News Focus
News Focus
Post# of 20689
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 05/09/2012 5:15:00 PM

Wednesday, May 09, 2012 5:15:00 PM

Post# of 20689
Outlook for 2012 US Copaxone sales (three posts):

#msg-75390703
#msg-75406710
#msg-75406857

The bottom line, IMO, is that 2012 US sales of Copaxone (assuming no generic) will be in the neighborhood of $2.6B.

According to Teva, in 1Q12, Copaxone had a 40.2% TRX share of the US market—the highest of any MS drug.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote